A proposed bridging approach for the assessment of novel tobacco products
|
|
|
- Rachel James
- 5 years ago
- Views:
Transcription
1 A proposed bridging approach for the assessment of novel tobacco products Dr. Ian M. Fearon British American Tobacco (Investments) Limited R&D Centre Southampton, U.K.
2 Agenda Insight into BAT R&D Evolution of next generation products across the risk spectrum Multidisciplinary approach to demonstrate the reduced risk potential of next generation products Bridging data between product variants: a new requirement in the fast paced world of novel nicotine and tobacco products
3 Agenda Insight into BAT R&D Evolution of next generation products across the risk spectrum Multidisciplinary approach to demonstrate the reduced risk potential of next generation products Bridging data between product variants: A new requirement in the fast paced world of novel nicotine and tobacco products
4 R&D at British American Tobacco Global R&D reach 1200 scientists and technologists > 50 scientific disciplines 0.5Bn R&D expenditure since , over 3000 patents filed, over 1800 granted BAT Sites Collaborators
5 An open approach to R&D Visitors Conferences Publications Social Media Over 1500 visitors to our R&D Live Centre at Global R&D since 2011 Presentation of data at global scientific & regulatory conferences and hosting of conferences on site Over 180 publications since 2008 Website and Twitter feed dedicated to science
6 Agenda Insight into BAT R&D Evolution of next generation products across the risk spectrum Multidisciplinary approach to demonstrate the reduced risk potential of next generation products Bridging data between product variants: a new requirement in the fast paced world of novel nicotine and tobacco products
7 BAT is investing in a range of products across the risk spectrum
8 E-cigarettes have evolved rapidly Development of e-liquids
9 Toxicants cause harm (not nicotine) What is the source of toxicants in NGPs? Cigarettes Approximate number of compounds found in aerosol Toxicants from burning tobacco Toxicants transferred from tobacco Other potential sources of toxicants >6,500 Yes Yes Combustion / pyrolysis of cigarette paper
10 Toxicants cause harm (not nicotine) What is the source of toxicants in NGPs? Cigarettes THP Vapour Approximate number of compounds found in aerosol Toxicants from burning tobacco Toxicants transferred from tobacco >6, Yes Trace No tobacco Yes Yes No tobacco Other potential sources of toxicants Combustion / pyrolysis of cigarette paper Thermal degradation of PG/VG & flavours; leachables from device materials Thermal degradation of PG/VG & flavours; leachables from device materials
11 The mathematics of risk Risk = exposure x longevity of use Exposure = emissions x use
12 E-cigarettes - a reduced risk product? While vaping may not be 100% safe, most of the chemicals causing smoking-related disease are absent and the chemicals which are present pose limited danger. It has been previously estimated that EC are around 95% safer than smoking. This appears to remain a reasonable estimate. Although it is not possible to quantify the long-term health risks associated with e-cigarettes precisely, the available data suggest that they are unlikely to exceed 5% of those associated with smoked tobacco products, and may well be substantially lower than this figure.
13 E-cigarettes - a reduced risk product?
14 E-cigarettes - a reduced risk product?
15 Need for product assessment Novel tobacco and nicotine products have rapidly increased in popularity over the last 5 years Mainly driven by rapid innovation with new products and e-liquids introduced to the market place that have constantly evolved to meet smokers needs Potential frameworks for assessing the individual- and population-level risks associated with product introduction FDA PMTA/MRTP TPD2 These mandate submission of data package prior to marketing/approval
16 Stewardship of e-cigarettes Requirements of and additional to TPD2 e-liquid What s in the liquid? Device What s the device made of? Does it conform to electrical safety? Product What s in the vapour? How stable is the product over time? How is it used? Stewardship of e-cigarette flavours S. Costigan and C. Meredith Regul Toxicol Pharmacol 72: , 2015
17 Agenda Insight into BAT R&D Evolution of next generation products across the risk spectrum Multidisciplinary approach to demonstrate the reduced risk potential of next generation products Bridging data between product variants: A new requirement in the fast paced world of novel nicotine and tobacco products
18 Reduced risk substantiation TPD2 provides a regulatory standard which all manufacturers must meet Greater datasets are required if you want to go further exposure reduction assessment risk reduction assessment These datasets may need to be submitted to regulators where mandated but may also be consumer-facing
19 10 steps to substantiating the risk reduction potential of tobacco & nicotine products
20 Conundrum How do regulators, public health scientists and product manufacturers keep innovating and improving novel products to ensure that smokers start to use and keep using these new products, while allowing their timely safety assessment and approval?
21 Hypothetical scenario Product has demonstrated reduced-risk potential and is on the market
22 Hypothetical scenario Innovation drives down toxicant emissions, potentially enhancing the risk reduction Ideally:
23 Hypothetical scenario Innovation drives down toxicant emissions, potentially enhancing the risk reduction Practically: 3-year research package 6-month regulatory approval How do we reduce this time, while maintaining safety?
24 Agenda Insight into BAT R&D Evolution of next generation products across the risk spectrum Multidisciplinary approach to demonstrate the reduced risk potential of next generation products Bridging data between product variants: A new requirement in the fast paced world of novel nicotine and tobacco products
25 Pharma approach to the issue Many drug regulators allow bridging studies to bring existing foreign medicines to new market.provides guidance with respect to regulatory and development strategies that will permit adequate evaluation of the influence of ethnic factors while minimizing duplication of clinical studies and supplying medicines expeditiously to patients for their benefit.
26 Can a derivation of this model be applied to nicotine and tobacco products? Assumptions: e-cigarettes are a reduced risk product chemical emissions are the key determinants of risk a reduced risk product needs to be on the market to be a reduced risk product there is a fundamental need for stewardship
27 Can a derivation of this model be applied to nicotine and tobacco products?
28 Can a derivation of this model be applied to nicotine and tobacco products?
29 Can a derivation of this model be applied to nicotine and tobacco products?
30 Can a derivation of this model be applied to nicotine and tobacco products?
31 Can a derivation of this model be applied to nicotine and tobacco products?
32 Can a derivation of this model be applied to nicotine and tobacco products?
33 Can a derivation of this model be applied to nicotine and tobacco products?
34 Summary Product innovation necessary to drive incremental increases in performance Public health potential of novel products requires rapid product assessment to place products on market Modified pharma industry approach to bridging could be applied in the nicotine and tobacco product context Foundation datasets can be added to on a need basis to allow bridging to a novel product
35 British American Tobacco (Investments) Limited All rights reserved. No part of these materials may be reproduced in any form or by any means without the prior written consent of British American Tobacco (Investments) Limited and no responsibility or liability is accepted for any third party reliance on any data contained herein. The data and information used in these materials has been compiled from a number of sources.
Next Generation Products Sandra Costigan, Marianna Gaca, ChuanLiu, Kevin McAdam, James J. Murphyand Christopher Proctor British American Tobacco 21
Next Generation Products Sandra Costigan, Marianna Gaca, ChuanLiu, Kevin McAdam, James J. Murphyand Christopher Proctor British American Tobacco 21 st October 2015 Contents Evolution of products across
The concept that not all tobacco and nicotine products
A Model Risk Continuum for Tobacco and Nicotine Products by Chris Proctor, Sudhanshu Patwardhan, and James Murphy The concept that not all tobacco and nicotine products present the same risks to human
00:08 For decades our scientists have endeavoured to reduce the risks of tobacco use and continue to do so today. 00:15
00:00 British American Tobacco 00:02 00:03 The Electronic Cigarette 00:07 00:08 For decades our scientists have endeavoured to reduce the risks of tobacco use and continue to do so today. 00:15 00:15 Our
Might Smoking Rates go up in Flames? Dr John Schoonbee, Chief Medical Officer, Swiss Re
Might Smoking Rates go up in Flames? Dr John Schoonbee, Chief Medical Officer, Swiss Re 2 Agenda Smoking is still a problem Stopping is hard Electronic cigarettes Reduced Risk tobacco products Males >15yr
RNA-SEQ based toxicogenomics comparison of airway cells exposed to Vype TM epen vapour and cigarette smoke.
RNA-SEQ based toxicogenomics comparison of airway cells exposed to Vype TM epen vapour and cigarette smoke Emmanuel Minet, PhD CBTOX 2017, Goiânia emmanuel_minet@bat.com CONFLICT OF INTEREST STATEMENT
Responsible Practice in E-Vapour Products (EVP) Product Stewardship
Responsible Practice in E-Vapour Products (EVP) Product Stewardship Tanvir Walele, MSc, ERT 11 October 2016 1 Responsible Practice Responsible practice can be divided in to 3 areas: Pre-market product
Policy Options for the Regulation of Electronic Cigarettes
Policy Options for the Regulation of Electronic Cigarettes Consultation submission Your details This submission was completed by: (name) Philip Hope / Assoc Prof Chris Atkinson Address: (street/box number)
Rationale for Establishing Tobacco Product Regulation
Rationale for Establishing Tobacco Product Regulation Erik Dybing, MD, PhD Conference of the Parties Technical Briefing Geneva, 7 February 2006 WHO Strategy for Tobacco Control Preventing uptake of tobacco
Smoking, e-cigs and reduced risk products. Dr John Schoonbee, IMS November 2017
Smoking, e-cigs and reduced risk products Dr John Schoonbee, IMS November 2017 2 The storyline smoking is bad yet many folks still smoke because quitting is very hard is it better, if one cannot quit,
Electronic cigarettes: Pre-clinical and clinical assessment
Disclaimer: The information in these materials is a formal dissemination of information by BAT and issues discussed in my presentation are not in any official manner related to/voiced by EUROTOX or its
The English experience in a European regulatory context. E-cigarette summit Washington DC 1 st May 2018 Deborah Arnott Chief Executive ASH (UK)
The English experience in a European regulatory context E-cigarette summit Washington DC 1 st May 2018 Deborah Arnott Chief Executive ASH (UK) Declaration of Interest ASH (UK) is a public health charity
Modified Risk Tobacco Product Applications A Succinct ENDS Industry Perspective
Modified Risk Tobacco Product Applications A Succinct ENDS Industry Perspective Patricia I. Kovacevic General Counsel, Chief Compliance Officer Presentation to the Food and Drug Law Institute Tobacco Conference,
ELECTRONIC CIGARETTES WHAT S THE BOTTOM LINE?
ELECTRONIC CIGARETTES WHAT S THE BOTTOM LINE? E-cigarettes have the potential to benefit adult smokers who are not pregnant if used as a complete substitute for regular cigarettes and other smoked tobacco
Smoking Harm Reduction: If Not Now When?
Smoking Harm Reduction: If Not Now When? K. Michael Cummings, PhD, MPH Medical University of South Carolina The E-Cigarette Summit Washington DC, April 30, 2018 Outline for my talk Historical context,
Physical and chemical properties of cigarette, heated tobacco and e-cigarette aerosols
SPS3 N2ff Physical and chemical properties of cigarette, heated tobacco and e-cigarette aerosols Caner U Yurteri, Jennifer Margham, Kevin McAdam, Mark Forster, Chuan Liu, Chris Wright, Derek Mariner, Chris
Survey to Measure the Effectiveness of Electronic Cigarettes - October 2012
Survey to Measure the Effectiveness of Electronic Cigarettes - October 2012 Survey concludes that e-cigarette users feel better, have the support of friends and family, and save money compared to buying
GLOBAL TOBACCO REGULATION OVERVIEW IVAN GENOV RESEARCH ANALYST 31 MAY 2018
IVAN GENOV RESEARCH ANALYST 31 MAY 2018 Three tiers of regulations affecting the industry 2 Core Advertising and sponsorship bans Descriptor bans Tax-driven excise increases Standard Public smoking bans
Industry Post-Regulation. E-Cigarette Summit Tim Phillips, ECigIntelligence. 17 th November
Industry Post-Regulation E-Cigarette Summit 217 Tim Phillips, ECigIntelligence 17 th November 217 www.ecigintelligence.com Agenda 1 2 3 Post-TPD: Has regulation been a success? Heated Tobacco: a success?
Global E-Cigarette Market- Industry Analysis & Outlook ( )
Global E-Cigarette Market- Industry Analysis & Outlook (2016-2020) ----------------------------------------- Executive Summary Electronic cigarettes, also known as E-cigarettes, electronic nicotine delivery
E.cigarettes. An alternative to a uniquely deadly product that kills one in two of its regular users? Paul Lambert Public Health, Leeds City Council
E.cigarettes An alternative to a uniquely deadly product that kills one in two of its regular users? Paul Lambert Public Health, Leeds City Council Background First came to market about 10 years ago, with
DECISION. Recalling further its decision FCTC/COP5(6) to adopt further partial guidelines;
66 Conference of the Parties to the WHO Framework Convention on Tobacco Control Seventh session Delhi, India, 7 12 November 2016 12 November 2016 DECISION FCTC/COP7(14) Further development of the partial
Nicotine delivery from e-cigarettes part I: study designs for two pharmacokinetic studies.
LOS ANGELES CLINICAL TRIALS Nicotine delivery from e-cigarettes part I: study designs for two pharmacokinetic studies. Ian M. Fearon, Alison Eldridge, Nathan Gale, Christopher J. Shepperd, Mike McEwan,
E-Cigarette Product Regulation and Standardisation
E-Cigarette Product Regulation and Standardisation Derek Mariner British American Tobacco, Research & Development, Southampton UK E-cigarette Workshop, Paper STW03 CORESTA Smoke Science and Product Technology
Kevin Walton, Ph.D. Chief, Clinical Research Grants Branch Division of Therapeutics and Medical Consequences NIDA. No disclosures
Kevin Walton, Ph.D. Chief, Clinical Research Grants Branch Division of Therapeutics and Medical Consequences NIDA No disclosures NIDA Organizational Chart Office of Diversity & Health Disparities Office
Regulatory Support for Tobacco Products. Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help.
Regulatory Support for Tobacco Products Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help. PREMARKET TOBACCO (PMTA) HUMAN FACTORS STUDIES SUBSTANTIAL EQUIVALENCE
Policy Options for the Regulation of Electronic Cigarettes
Policy Options for the Regulation of Electronic Cigarettes Consultation submission Your details This submission was completed by: Address: (name) Mark Forsyth (street/box number) 3 Queens Wharf (town/city)
Texas Bill to Regulate Vapor Products. Over the past few years, electronic cigarettes, also commonly referred to as e-cigarettes
Texas Bill to Regulate Vapor Products Over the past few years, electronic cigarettes, also commonly referred to as e-cigarettes or vapor, have been trending all over the state of Texas as a tobacco alternative,
Sub-components in Nicotine cessation products?
Sub-components in Nicotine cessation products? Mr Arun Sarda, Director of Quality and Regulatory Affairs Member of the HEITKAMP & THUMANN GROUP Regulatory approval of sub-components in nicotine cessation
Policy Options for the Regulation of Electronic Cigarettes
Policy Options for the Regulation of Electronic Cigarettes Consultation submission This submission was completed by: (name) Position (if applicable): Evon Currie General Manager, Community and Public Health
UK E-Cigarette Summit Relative risks of cancer posed by combustible and vapourising forms of nicotine delivery: Evidence from chemical exposures
UK E-Cigarette Summit 2017 Relative risks of cancer posed by combustible and vapourising forms of nicotine delivery: Evidence from chemical exposures Ed Stephens University of St Andrews Scope of presentation
RE: Docket No. FDA-2014-N , Electronic Cigarettes and the Public Health
VIA ELECTRONIC SUBMISSION June 30, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 RE: Docket No. FDA-2014-N-1936-0001, Electronic
04 WE ARE DEVELOPING SAFER CHOICES 06 WE WORK AS PARTNERS 08
We are BAT2016 02 WE LEAD THE WAY 04 WE ARE DEVELOPING SAFER CHOICES 06 WE WORK AS PARTNERS 08 WE ARE A TOP EMPLOYER 10 WE OPERATE RESPONSIBLY 1 We are one of the world s leading multinational companies.
The Latest on Vaping Among U.S. Teens
The Latest on Vaping Among U.S. Teens Jon Macy, PhD, MPH Indiana University School of Public Health Bloomington Presentation Outline Overview of Electronic Nicotine Delivery Systems (ENDS) New Prevalence
Modelling the effects of user exposure to harmful emissions across the spectrum of nicotine delivery
Global Nicotine Forum 2018 Modelling the effects of user exposure to harmful emissions across the spectrum of nicotine delivery Ed Stephens University of St Andrews Declaration: No conflicts of interest
HARM REDUCTION The opportunity
HARM REDUCTION The opportunity Sustainability Focus Report 2014 CLICK TO READ 1 8 STEP INSIDE: VIDEO TOUR OF OUR R&D LABS HARM REDUCTION A NEW WAY FORWARD? WHAT IS HARM REDUCTION? 2 7 TRANSPARENCY AND
A combination of licensed medication and professional support is four times more likely to achieve a stop in smoking behaviour.
PHA Position Statement E-cigarettes 30 May 2014 The Public Health Agency (PHA) considers E-cigarettes with caution at this time. E-cigarettes are not licensed nicotine replacement products. They are not
Why comprehensive TC is essential for successful harm reduction
Why comprehensive TC is essential for successful harm reduction E-cigarette summit London 15 th November 2018 Deborah Arnott Chief Executive ASH (Action on Smoking and Health) Declaration of Interest ASH
Development and validation of a device for measuring puffing topography of e-cigarette users
Development and validation of a device for measuring puffing topography of e-cigarette users CUNNINGHAM A. 1 ; SLAYFORD S. 1 ; VAS C. 1 ; GEE J. 1 ; COSTIGAN S. 2 ; PRASAD K. 1 1 British American Tobacco,
Reduced-Risk Products Science Update
Reduced-Risk Products Science Update Dr. Ian Jones, PhD JTI VP, Reduced-Risk Products Science Forward-Looking Statements This presentation contains forward-looking statements. These statements appear in
UPDATES FROM THE FDA CENTER FOR TOBACCO PRODUCTS (CTP)
UPDATES FROM THE FDA CENTER FOR TOBACCO PRODUCTS (CTP) Mitch Zeller, J.D. Director, FDA May 4, 2017 CENTER FOR TOBACCO PRODUCTS AGENDA Update on Regulations and Guidances: Deeming Update on Science Update
E-cigarette consumption and puffing topography data. Dr Sudhanshu Patwardhan FDA CTP Workshop, Hyattsville, Maryland. March 9, 2015.
E-cigarette consumption and puffing topography data Dr Sudhanshu Patwardhan FDA CTP Workshop, Hyattsville, Maryland. March 9, 2015. Outline Nicoventures Introduction Topography and use patterns to inform
Non-Industry Voices on Tobacco Harm Reduction and Vaping Products
HALO + EVO + PURITY Non-Industry Voices on Tobacco Harm Reduction and Vaping Products Hosted by: Patricia Kovacevic General Counsel, Chief Compliance Officer June 2016 Nothing herein shall be interpreted
Towards a Smokefree Generation: A Tobacco Control Plan for England. Tim Baxter, Department of Health, England
Towards a Smokefree Generation: A Tobacco Control Plan for England 1 Tim Baxter, Department of Health, England Smoking rates are falling fast... 25 Adult Smoking prevalence in England (daily and non daily)
REGULATORY OPTIONS FOR MOVING TO THE ELIMINATION OF SMOKING. Ron Borland PhD
REGULATORY OPTIONS FOR MOVING TO THE ELIMINATION OF SMOKING Ron Borland PhD Tobacco Smoking Extremely harmful to health Kills over half of long-term users Reduces quality life years in most Slows recovery
A study to examine changes in exposure to cigarette smoke chemicals when a smoker switches to using a tobacco heating product. Part I: Study Design.
A study to examine changes in exposure to cigarette smoke chemicals when a smoker switches to using a tobacco heating product. Part I: Study Design. Nathan Gale 1, Mike McEwan 1, Alison Eldridge 1, Neil
UNITED STATES REGULATION OF TOBACCO PRODUCTS. Presented by Mitch Zeller Center Director FDA Center for Tobacco Products
UNITED STATES REGULATION OF TOBACCO PRODUCTS Presented by Mitch Zeller Center Director FDA Center for Tobacco Products May 24, 2016 OVERVIEW OF TODAY S PRESENTATION Highlights of the Deeming Final Rule
FROM TOBACCO TO SOMETHING BETTER
FROM TOBACCO TO SOMETHING BETTER OUR APPROACH TO NEXT GENERATION PRODUCTS www.imperialbrandsplc.com WELCOME Imperial Brands is a dynamic fast moving consumer goods company borne out of a strong tobacco
National Conference of State Legislatures Legislative Summit: Clearing the Air About E-Cigarettes
National Conference of State Legislatures Legislative Summit: Clearing the Air About E-Cigarettes Jack Henningfield Ph.D. Vice President, Research and Health Policy Pinney Associates And Professor, Adjunct,
Experimental trial on the effectiveness of IQOS compared to e-cigarettes and regular tobacco cigarettes
Global Forum on Nicotine Rethinking Nicotine 2018 Experimental trial on the effectiveness of IQOS compared to e-cigarettes and regular tobacco cigarettes Effects on acute craving, withdrawal, positive
Claims about health in ads for e-cigarettes. CAP and BCAP s regulatory statement
Claims about health in ads for e-cigarettes CAP and BCAP s regulatory statement Contents 1. Executive Summary... 2 2. Policy background and the decision to consult... 4 3. Decisions... 6 4. Consequence
Guideline for Advertising of e-cigarettes
GUIDELINE 43 Guideline for Advertising of e-cigarettes Last Updated May 2015 What kind of product is this guideline for? What is the purpose of this guideline? Electronic, or e-cigarettes, are battery
Effect of Sugars on Selected Toxicant Yields in e-cigarettes
CORESTA Congress, 11th October 2016, Berlin Effect of Sugars on Selected Toxicant Yields in e-cigarettes Jennifer Margham 1, Kevin McAdam 1 ST 31 BERLIN 2016 1 British American Tobacco, Group R&D, Southampton,
Consultation on Electronic Cigarettes. Analysis of submissions
Consultation on Electronic Cigarettes Analysis of submissions Released 2017 health.govt.nz Citation: Ministry of Health. 2017. Consultation on Electronic Cigarettes: Analysis of submissions. Wellington:
Addressing the Challenge of ENDS Regulation. David Graham President & Managing Partner Reveritas Group
Addressing the Challenge of ENDS Regulation David Graham President & Managing Partner Reveritas Group Addressing the Challenge of ENDS Regulation 1. The context of conflict and effect of the crossfire
Dissolvable Tobacco Products
Dissolvable Tobacco Products James E. Dillard Senior Vice President, Regulatory Affairs Altria Client Services 1 l Altria Client Services (on behalf of PM USA and USSTC) I Presentation to the Tobacco Products
Peter G. Shields, MD Tobacco Products Scientific Advisory Committee (TPSAC) August 16, 2013
Peter G. Shields, MD Tobacco Products Scientific Advisory Committee (TPSAC) August 16, 2013 Conceptual Framework for Evaluating MRTPs: Objectives Provide a framework for evaluating all tobacco products
E-cigarettes: Evidence, perceptions and misconceptions. Martin Dockrell, Tobacco Control Programme Lead
E-cigarettes: Evidence, perceptions and misconceptions Martin Dockrell, Tobacco Control Programme Lead Smoking causes the greatest number of preventable deaths Are EC less tightly regulated in the UK than
Competition in the Vaporized Nicotine Market and its Potential Impact on the Cigarette Market. David T. Levy Georgetown University
Competition in the Vaporized Nicotine Market and its Potential Impact on the Cigarette Market David T. Levy Georgetown University The E-Cigarette Summit: Science, Regulation and Public Health Washington,
MARKETING STANDARDS FOR MEMBERSHIP
MARKETING STANDARDS FOR MEMBERSHIP The Vapor Technology Association (VTA) is a leading national trade association in the electronic cigarette and vapor product industry. VTA represents the manufacturers,
Defining the future of health care and developing tomorrow s Innovators.
Defining the future of health care and developing tomorrow s Innovators. 2019 Medical Marvels Research Competition A research competition for 9th and 10th grade students Sponsored by the Feinstein Institute
Policy making at the American Chemical Society (ACS) - developing a statement on scientific integrity
Policy making at the American Chemical Society (ACS) - developing a statement on scientific integrity Chris Proctor and Sarah Cooney CINF seminar, Boston, August 18, 2015 Overview Why scientific integrity
Exploring five common claims about e-cigarette use. Lion Shahab, PhD University College
Exploring five common claims about e-cigarette use Lion Shahab, PhD University College London @LionShahab Claim 1: Renormalisation Claim 1: Renormalisation A priori predictions for impact on population
BRITISH AMERICAN TOBACCO Science & Technology report
BRITISH AMERICAN TOBACCO Science & Technology 2015 report Foreword 1 Dr David O Reilly, Group Scientific and R&D Director RESEARCH PRIORITIES Stewardship and next generation products 2 Dr Christopher Proctor
Cardiovascular effects of nicotine vs. cigarette smoke
Cardiovascular effects of nicotine vs. cigarette smoke Dr Konstantinos Farsalinos Researcher Onassis Cardiac Surgery Center, Greece University of Patras, Greece National School of Public Health, Athens-Greece
How Might Medicinal Regulators Evolve in their Expectations for ENDS? David M Graham Chief Impact Officer - NJOY
How Might Medicinal Regulators Evolve in their Expectations for ENDS? David M Graham Chief Impact Officer - NJOY 4 Years Ago The Regulation of Nicotine-Containing Products Jeremy Mean 2015 The fact that
DRAFT FOR COMMENT ( ) All Tobacco Products are Deadly and Addictive: Product Diversity Challenges Regulation and Communication
DRAFT FOR COMMENT (24.01.06) All Tobacco Products are Deadly and Addictive: Product Diversity Challenges Regulation and Communication Jack E. Henningfield, PhD Conference of the Parties Technical Briefing
RISK FROM E-VAPOUR PRODUCTS FOR USERS AND BYSTANDERS
RISK FROM E-VAPOUR PRODUCTS FOR USERS AND BYSTANDERS Dr Konstantinos Farsalinos Researcher Onassis Cardiac Surgery Center, Greece University of Patras, Greece COI Past 36 months 1 study funded by non-profit
Menthol Cigarette Report
Menthol Cigarette Report Tobacco Products Scientific Advisory Committee Meeting July 15, 2010 Corinne G. Husten, MD, MPH Senior Medical Advisor Center for Tobacco Products, FDA 1 Menthol Cigarette Report
The importance of offering adult smokers a portfolio of potentially less harmful products
The importance of offering adult smokers a portfolio of potentially less harmful products International Symposium on Nicotine Technology June 15 th 2017 Thomas Mc Grath, PhD PMI R&D, Philip Morris Products
Electronic cigarettes disruptive innovation, public health potential and regulatory challenge
HIT Hot Topics Conference 2014 Electronic cigarettes disruptive innovation, public health potential and regulatory challenge Prof Gerry Stimson Knowledge Action Change and Emeritus Professor Imperial College
ESPs are battery-operated devices that contain cartridges filled with liquid chemicals. The chemicals turn into a vapour that the user inhales (this
ESPs are battery-operated devices that contain cartridges filled with liquid chemicals. The chemicals turn into a vapour that the user inhales (this is called vaping). They do not contain tobacco. They
Advancing Use of Patient Preference Information as Scientific Evidence in Medical Product Evaluation Day 2
Advancing Use of Patient Preference Information as Scientific Evidence in Medical Product Evaluation Day 2 Theresa Mullin, PhD Director, Office of Strategic Programs FDA Center for Drug Evaluation and
MDQuit Best Practices Conference January 26, Presented by William C. Tilburg Deputy Director
MDQuit Best Practices Conference January 26, 2017 Presented by William C. Tilburg Deputy Director Founded in 2001 Partnership between UM School of Law, DHMH, and Maryland Office of the Attorney General
Introduction. Principles
NHS Health Scotland s position statement on Electronic Nicotine Delivery Systems ENDS - e-cigarettes and other smoking simulator products 31 October 2014 Introduction NHS Health Scotland is the national
Modeling the Population Health Effects of Camel Snus with Reduced Risk Information
Modeling the Population Health Effects of Camel Snus with Reduced Risk Information Geoffrey Curtin, Ph.D. - RAI Services Company Annette Bachand, Ph.D., Sandra Sulsky, Ph.D. - Ramboll Environ; Saul Shiffman,
E-Cigarettes: Current Perspective
E-Cigarettes: Current Perspective Aruni Bhatnagar, Ph.D. Professor of Medicine University of Louisville Louisville, KY Electronic Cigarettes E-cigarettes are electronic nicotine delivery systems (ENDS),
Electronic cigarettes: A new era for tobacco harm reduction Adapted for SW Specialist Nurses for Children in Care meeting 17 January 2017
Electronic cigarettes: A new era for tobacco harm reduction Adapted for SW Specialist Nurses for Children in Care meeting 17 January 2017 Russ Moody Health & Wellbeing Programme Lead Public Health England
E-Cigarettes and Health Care:
E-Cigarettes and Health Care: What They Mean for Hospitals and Clinicians The increasing popularity of electronic cigarettes or e-cigarettes is forcing hospitals and clinicians to determine what to recommend
Bill. amending the Tobacco Control Act, No. 6/2002, with subsequent amendments. From the Minister of Health.
146 th Legislative session, 2016 2017. Parliamentary document x x. matter. Government bill. Bill amending the Tobacco Control Act, No. 6/2002, with subsequent amendments. From the Minister of Health. Article
E-Vapour (EVAP) Sub-Group 2017 Report. Kitzbühel, Austria October 10, 2017
E-Vapour (EVAP) Sub-Group 2017 Report Kitzbühel, Austria October 10, 2017 History Evolution o 2014, formation of E-cigarette TF o 2016, TF activities completed; formation of E-vapor product SG 2 E-Vapour
Discussion points on Bill S-5
Disclaimer: The following document was developed to provide a brief set of discussion points for individuals wishing to discuss Bill S-5 with policy makers, politicians, senators or their advisers. It
HARM REDUCTION The opportunity
HARM REDUCTION The opportunity Sustainability Focus Report 2014 Introduction HARM REDUCTION A NEW WAY FORWARD? OUR CHIEF EXECUTIVE This is an exciting time to be leading British American Tobacco. We have
Stop the Vape. Maria Hines RN, MSN. Denise Kneubuhler RN, MSN
Stop the Vape Maria Hines RN, MSN Denise Kneubuhler RN, MSN https://78.media.tumblr.com/3a5eee652f16d0327cf3f4d8 8a63706c/tumblr_nzpw68ossS1rc7zl1o1_500.gif Objectives Increase awareness and knowledge
E-Cigarette Update: Secondhand Vapour
E-Cigarette Update: Secondhand Vapour Toxicity and Health Effects The popularity of e-cigarettes continues to increase, with more Canadians than ever using them indoors and out. The scientific evidence
Improving E-Cigarette Research through Measurement and Design ANDREA VILLANTI, PHD MPH E-CIGARETTE SUMMIT MAY 8, 2017
Improving E-Cigarette Research through Measurement and Design ANDREA VILLANTI, PHD MPH E-CIGARETTE SUMMIT MAY 8, 2017 Disclosures Andrea Villanti, PhD, MPH Director for Regulatory Science and Policy The
Strategic Plan Executive Summary Society for Research on Nicotine and Tobacco
Strategic Plan 2013 2017 Executive Summary Society for Research on Nicotine and Tobacco Prepared By: Corona Insights Corona Insights, 2012 CoronaInsights.com CONTENTS Introduction... 1 Background... 1
Executive Summary. No Fire, No Smoke: The Global State of Tobacco Harm Reduction 2018
Executive Summary Executive Summary No Fire, No Smoke: The Global State of Tobacco Harm Reduction 2018 3 The GSTHR report maps for the first time the global, regional and national availability and use
Prevent disease Protect from injury Promote healthy lifestyles
https://youtu.be/9dzs_rniak0 Prevent disease Protect from injury Promote healthy lifestyles Objectives 1. Obtain a better understanding of local policies that make a difference 2. Establish a plan of action
DIRECTIVE 2014/40/UE AND TRANSPOSITION IN ITALY: LEGISLATIVE DECREE OF 12 JANUARY 2016, N. 6
DIRECTIVE 2014/40/UE AND TRANSPOSITION IN ITALY: LEGISLATIVE DECREE OF 12 JANUARY 2016, N. 6 The DIRECTIVE 2014/40 / EU (TPD: Tobacco Products Directive) of the European Parliament and of the Council of
Harmful and potentially harmful constituents in e-cigarettes
Harmful and potentially harmful constituents in e-cigarettes Prof. Riccardo Polosa Institute of Internal Medicine Centre for the Prevention and Cure of Tabagism University of Catania - ITALY Global Forum
22nd Century Group, Inc. (XXII - $ Buy)
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.47 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
Nicotine Reduction Workshop Role of nicotine in smoking behaviour
Nicotine Reduction Workshop Role of nicotine in smoking behaviour Derek Mariner APSTW02 11 October 2016 2016 CORESTA Congress, Berlin, Germany, 9-13 October 2016 Introduction Nicotine itself is not especially
Prof Linda Bauld 1,2,3, Kathryn Angus 1,3, Dr Marisa de Andrade 3,4, Dr Allison Ford 1,2,3
Prof Linda Bauld 1,2,3, Kathryn Angus 1,3, Dr Marisa de Andrade 3,4, Dr Allison Ford 1,2,3 1. Institute for Social Marketing, University of Stirling 2. Centre for Tobacco Control Research, University of
Disentangling the gateway hypothesis: does e-cigarette use cause subsequent smoking in adolescents?
Disentangling the gateway hypothesis: does e-cigarette use cause subsequent smoking in adolescents? Lion Shahab, PhD University College London @LionShahab Background Background A priori considerations
Improving the regulatory framework for electronic cigarettes (e-cigarettes) and emerging tobacco and nicotine-delivery products
[In Confidence] Office of the Associate Minister Health Chair, Cabinet Improving the regulatory framework for electronic cigarettes (e-cigarettes) and emerging tobacco and nicotine-delivery products Proposal
22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
The Changing Landscape of Tobacco: E-Cigarettes, E-Hookahs and More
38th Annual Family Medicine Intensive Review Course The Changing Landscape of Tobacco: E-Cigarettes, E-Hookahs and More Debbie Rushing, LADAC, CTTS-M Associate Branch Chief Tobacco Prevention and Cessation
FDLI s Enforcement, Litigation, and Compliance Conference. Center for Tobacco Products Office of Compliance and Enforcement 2017 Update
FDLI s Enforcement, Litigation, and Compliance Conference Center for Tobacco Products Office of Compliance and Enforcement 2017 Update Ann Simoneau, Director Office of Compliance and Enforcement Center
AN UPDATE ON FDA S COMPREHENSIVE PLAN ON TOBACCO AND NICOTINE
AN UPDATE ON FDA S COMPREHENSIVE PLAN ON TOBACCO AND NICOTINE Mitch Zeller, J.D. Director, FDA May 3, 2018 CENTER FOR TOBACCO PRODUCTS HOW CAN WE MAKE THE GREATEST IMPACT? We truly find ourselves at a